NEW YORK (PRWEB) September 23, 2019
Rivews, a company that provides healthcare organizations with a text-message platform that enables them to instantly survey patients after-care, is proud to announce its acquisition by EMPATHIQ, a technology company that develops patient experience solutions.
"We’re proud of how far we’ve come, especially considering we’ve entirely bootstrapped this company over the course of the past three years. This acquisition will enable both parties in addressing one of the most important bottomline components of healthcare, patient experience and outcomes," said Yasir Ali, co-founder and CEO. "We’ve seen a proliferation of phenomenal patient engagement solutions over the years improving patient experience and satisfaction, yet, we believe, only a very minuscule number actually address the collection of data on these patient experiences. Without real-time data, healthcare organizations are guessing how their patients actually feel. And because the vastly utilized survey platforms in the healthcare market, ranging from paper to email surveys, are very antiquated and lack data, we genuinely believe there’s a huge opportunity here. There's a lot under the hood that we're keeping in stealth-mode as both companies merge."
Rivews, founded in August of 2016, is a patient experience and reputation platform that enables healthcare organizations in instantly connecting with patients via text-message post-care. With nearly 1 in 3 patients engaging with Rivews' feedback management system, Rivews has engaged with over 1.8 million patients, with an average response rate of 28%. To date, Rivews has identified over 32,500 patient complaints with 17,500 of them including thorough and lengthy insight of additional comments sent by patients. The data has enabled Rivews to identify real-time patient satisfaction scores to better understand patient experiences by locations, providers, case and other metrics. The company, also a StartUp Health portfolio company, has been entirely bootstrapped and has partnerships with leading EHRs including AthenaHealth.
The acquisition will enable EMPATHIQ to further advance from its current online reporting and monitoring platform to enabling healthcare organizations in collection of real-time patient feedback and surveys after-care. The acquisition will also strengthen and give EMPATHIQ major advantage and leverage as it molds into a full-fledged patient experience software company.
“We’re excited to combine our capabilities and market presence with the talent and vision of the Rivews team.” said Walt Czerminski, CEO at EMPATHIQ. “The appetite for insight into patient experience and satisfaction is a natural extension of review management. We believe that Rivews' innovative platform will add value to our current clients and create valuable inroads to new markets. We’re very pleased to welcome the Rivews team and look forward to what we will accomplish with their platform and team."
EMPATHIQ is a software company that provides review management and patient experience software for health providers. EMPATHIQ helps individual health providers, hospitals, and health systems monitor and optimize their online reviews across 70+ health review sites. Using valuable review data, we help health providers and organizations understand how and wear to improve patient experience. Reputation marketing, Reviews management, Enterprise analytics, Business online presence, Review generation, Review marketing, Customer surveys, Social listening, Social publishing, Online Listings, Review Monitoring, Social Engagement, Listings, Business Insights, Webchat, Reviews and ratings, Customer experience management, Review Generation, Online business listings management.
Rivews is a patient experience and survey platform, enabling organizations in holistically collecting, assessing and understanding patient satisfaction scores in real-time. Rivews aggregates data such as provider names, locations, etc. to identify trends by a wide range of different metrics. Implemented at nearly 150 organizations, the platform has achieved over 1.8 million patient engagements with the leading patient survey response rate - 28%.